Who Supplies Plasma to India from SPAIN

To import finished pharmaceutical formulations containing plasma into India, foreign manufacturers must obtain an Import Registration Certificate and an Import License from the Central Drugs Standard Control Organization (CDSCO). The application process involves submitting Form 41 for registration and Form 10 for the import license. The registration certificate is valid for three years and requires a fee of $1,500 USD or its equivalent in Indian currency. An additional fee of $1,000 USD is required for registering each drug. The application process typically takes up to nine months.

Imported pharmaceutical formulations must undergo quality testing at CDSCO-approved laboratories. Three consecutive batches are required for testing, with samples provided for reanalysis. The applicant must pay the testing fees directly to the laboratory. Documentation required includes the Certificate of Analysis (CoA) from the exporting country, impurity standards, marker compounds, and reference standards. The testing process ensures compliance with Indian Pharmacopoeia standards and may take several weeks.

In April 2025, the CDSCO mandated that all imported drugs, including finished formulations containing plasma, must have valid import registration and licenses. This regulation aims to prevent the sale of unapproved or illegal medicines in the Indian market. The policy also stipulates that banned drugs manufactured in Special Economic Zones (SEZ) for export purposes are not allowed for transfer to the Domestic Tariff Area (DTA) for any purpose.

India imports finished plasma formulations to meet the demand for specialized treatments not available domestically. These include patented or branded formulations and specific dosage forms such as intravenous immunoglobulin (IVIG) and clotting factor concentrates. Domestic production may not suffice due to technological limitations or regulatory constraints. The market size for plasma-derived therapies in India is substantial, with a growing need for such treatments.

The import duty structure for HS Code 30029010 includes a Basic Customs Duty (BCD) of 10%, a Social Welfare Surcharge (SWS) of 10% of the BCD, and an Integrated Goods and Services Tax (IGST) of 0%. Therefore, the total landed duty is approximately 10.3% of the Cost, Insurance, and Freight (CIF) value. This structure is consistent for imports from Spain, as there are no specific exemptions or preferential rates for Spanish-origin goods.

Spain is a significant supplier of finished plasma formulations to India, offering high-quality products that meet international standards. Spanish manufacturers often provide patented formulations and specialized dosage forms not readily available from other sources. While other countries like China, Germany, and the United States also supply plasma-derived therapies, Spain's competitive advantage lies in its adherence to Good Manufacturing Practices (GMP) and the availability of unique formulations. Spain's share in India's plasma formulation import market is notable, reflecting its strong position.

India imports finished plasma formulations from Spain due to the availability of specialized treatments not produced domestically. Spanish manufacturers offer patented formulations and specific dosage forms that cater to unique medical needs in India. The high quality and compliance with international standards of Spanish products make them a preferred choice for Indian importers seeking reliable and effective plasma-derived therapies.

Compared to other sources like China, Germany, and the United States, Spain offers a competitive advantage in terms of product quality and regulatory compliance. Spanish manufacturers adhere to stringent Good Manufacturing Practices (GMP) and provide unique formulations not readily available from other countries. While other countries may offer lower prices, Spain's focus on quality and specialized products justifies the higher cost for Indian importers.

Importing finished plasma formulations from Spain involves certain risks, including dependency on a single source, currency fluctuations, and potential regulatory changes. Quality incidents or shipping disruptions can also impact the supply chain. To mitigate these risks, Indian importers should consider dual-sourcing strategies, maintain adequate inventory levels, and establish strong relationships with multiple suppliers.

1. 1Dual-Sourcing: Engage with multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain buffer stocks to manage supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC), Documents Against Payment (DA), or Documents Against Acceptance (DP).
4. 4Minimum Order Quantities (MOQs): Align order sizes with demand forecasts to optimize inventory costs.
5. 5Supplier Qualification: Conduct thorough due diligence to ensure suppliers meet quality and regulatory standards.

Implementing these strategies can enhance the resilience and efficiency of the procurement process for finished plasma formulations.

1. 1DGFT Importer Exporter Code (IEC): Obtain an IEC from the Directorate General of Foreign Trade.
2. 2CDSCO Registration (Form 41):